aTyr Pharma Inc. (ATYR)
aTyr Pharma Statistics
Share Statistics
aTyr Pharma has 88.86M shares outstanding. The number of shares has increased by 28.76% in one year.
| Shares Outstanding | 88.86M |
| Shares Change (YoY) | 28.76% |
| Shares Change (QoQ) | 5.86% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 86M |
| Failed to Deliver (FTD) Shares | 12.11K |
| FTD / Avg. Volume | 0.92% |
Short Selling Information
The latest short interest is 3.52M, so 4.19% of the outstanding shares have been sold short.
| Short Interest | 3.52M |
| Short % of Shares Out | 4.19% |
| Short % of Float | 4.29% |
| Short Ratio (days to cover) | 3.55 |
Valuation Ratios
The PE ratio is -4.2 and the forward PE ratio is -4.23. aTyr Pharma's PEG ratio is 0.49.
| PE Ratio | -4.2 |
| Forward PE | -4.23 |
| PS Ratio | 1143.94 |
| Forward PS | 0.5 |
| PB Ratio | 3.84 |
| P/FCF Ratio | -3.89 |
| PEG Ratio | 0.49 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for aTyr Pharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.48, with a Debt / Equity ratio of 0.19.
| Current Ratio | 5.48 |
| Quick Ratio | 5.48 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | -0.2 |
| Debt / FCF | -0.19 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $4.2K |
| Profits Per Employee | $-1.14M |
| Employee Count | 56 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0.99, so aTyr Pharma's price volatility has been higher than the market average.
| Beta | 0.99 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 3.6 |
| 200-Day Moving Average | 2.76 |
| Relative Strength Index (RSI) | 33.99 |
| Average Volume (20 Days) | 1.32M |
Income Statement
In the last 12 months, aTyr Pharma had revenue of 235K and earned -64.02M in profits. Earnings per share was -0.86.
| Revenue | 235K |
| Gross Profit | 235K |
| Operating Income | -67.91M |
| Net Income | -64.02M |
| EBITDA | -66.37M |
| EBIT | -67.91M |
| Earnings Per Share (EPS) | -0.86 |
Balance Sheet
The company has 11.05M in cash and 13.28M in debt, giving a net cash position of -2.23M.
| Cash & Cash Equivalents | 11.05M |
| Total Debt | 13.28M |
| Net Cash | -2.23M |
| Retained Earnings | -532.05M |
| Total Assets | 96.83M |
| Working Capital | 66.99M |
Cash Flow
In the last 12 months, operating cash flow was -69.12M and capital expenditures -65K, giving a free cash flow of -69.18M.
| Operating Cash Flow | -69.12M |
| Capital Expenditures | -65K |
| Free Cash Flow | -69.18M |
| FCF Per Share | -0.93 |
Margins
Gross margin is 100%, with operating and profit margins of -28899.57% and -27243.83%.
| Gross Margin | 100% |
| Operating Margin | -28899.57% |
| Pretax Margin | -27243.4% |
| Profit Margin | -27243.83% |
| EBITDA Margin | -28244.26% |
| EBIT Margin | -28899.57% |
| FCF Margin | -29440% |
Dividends & Yields
ATYR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ATYR is $16, which is 475.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $16 |
| Price Target Difference | 475.5% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Jul 1, 2019. It was a backward split with a ratio of 1:14.
| Last Split Date | Jul 1, 2019 |
| Split Type | backward |
| Split Ratio | 1:14 |
Scores
| Altman Z-Score | -3.49 |
| Piotroski F-Score | 0 |